



Accountant

Kala is an emerging pharmaceutical company on the verge of commercialization. We are seeking an experienced Accountant to join a growing and dynamic organization. This is an opportunity for the right individual to join Kala at a very exciting time. Come join an experienced and highly motivated team!

Key Responsibilities for this role will include:

- Accurate and timely completion of month end, quarter end and year end close responsibilities.
- Prepare and analyze balance sheet account reconciliations to the general ledger.
- Assist with analyzing financial statements on a monthly basis and report on variances. Preparation of audit schedules for the annual financial audit with external auditors.
- Support the development of and adherence to internal control processes
- Other projects as assigned

Our ideal candidate will have:

- BA/BS in Accounting
- Proficiency with Generally Accepted Accounting Principles (GAAP) in order to assist in preparation of financial statements
- CPA or CPA track preferred
- 5+ years of accounting experience.
- Highly detail oriented and organized.
- Previous experience at a publicly traded company
- Previous exposure to multiple ledgers (A/P, AR, General, Fixed Assets...)
- Excellent communication and interpersonal skills.
- Ability to learn quickly and manage multiple, competing priorities while maintaining a high degree of accuracy
- Experience with enterprise accounting software, Oracle preferred but not required

About Us:

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™(KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.